Prospects of targeted and immune therapies in SCLC

Lizza E L Hendriks, Jessica Menis, Martin Reck

Research output: Contribution to journalArticle

Abstract

INTRODUCTION: Small cell lung cancer (SCLC) is a tumor with a poor prognosis, often diagnosed in an advanced stage. Despite aggressive treatment of early and locally advanced disease, SCLC often relapses. First line chemotherapy provides good response rates in advanced disease, but progression free and overall survival are limited. New drugs such as some targeted therapies and immune therapies are promising in SCLC. Areas covered: In this review, we discuss the preclinical rationale and trial data for targeted therapies and immune therapies in SCLC, with a specific focus on clinical trials. Expert commentary: Lack of identification of clear prognostic and predictive biomarkers has limited the advances in treatment efficacy. This has most likely been the main cause of failure for compounds tested so far. Due to the highly mutational profile and the rapid growth pattern of SCLC, immunotherapy combined with chemotherapy seems the most promising treatment option. Concerning targeted agents, achievements made so far are small, but DLL3-antibodies or combinations of PARPi and immunotherapy could be very promising. These promising strategies also need testing in limited disease.

Original languageEnglish
Pages (from-to)1-17
Number of pages17
JournalExpert Review of Anticancer Therapy
DOIs
Publication statusE-pub ahead of print - Dec 28 2018

Fingerprint

Small Cell Lung Carcinoma
Immunotherapy
Therapeutics
Drug Therapy
Disease-Free Survival
Disease Progression
Biomarkers
Clinical Trials
Recurrence
Antibodies
Growth
Pharmaceutical Preparations
Neoplasms

Cite this

Prospects of targeted and immune therapies in SCLC. / Hendriks, Lizza E L; Menis, Jessica; Reck, Martin.

In: Expert Review of Anticancer Therapy, 28.12.2018, p. 1-17.

Research output: Contribution to journalArticle

@article{53d4581a33724862ab60960f09de3bba,
title = "Prospects of targeted and immune therapies in SCLC",
abstract = "INTRODUCTION: Small cell lung cancer (SCLC) is a tumor with a poor prognosis, often diagnosed in an advanced stage. Despite aggressive treatment of early and locally advanced disease, SCLC often relapses. First line chemotherapy provides good response rates in advanced disease, but progression free and overall survival are limited. New drugs such as some targeted therapies and immune therapies are promising in SCLC. Areas covered: In this review, we discuss the preclinical rationale and trial data for targeted therapies and immune therapies in SCLC, with a specific focus on clinical trials. Expert commentary: Lack of identification of clear prognostic and predictive biomarkers has limited the advances in treatment efficacy. This has most likely been the main cause of failure for compounds tested so far. Due to the highly mutational profile and the rapid growth pattern of SCLC, immunotherapy combined with chemotherapy seems the most promising treatment option. Concerning targeted agents, achievements made so far are small, but DLL3-antibodies or combinations of PARPi and immunotherapy could be very promising. These promising strategies also need testing in limited disease.",
author = "Hendriks, {Lizza E L} and Jessica Menis and Martin Reck",
year = "2018",
month = "12",
day = "28",
doi = "10.1080/14737140.2019.1559057",
language = "English",
pages = "1--17",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",

}

TY - JOUR

T1 - Prospects of targeted and immune therapies in SCLC

AU - Hendriks, Lizza E L

AU - Menis, Jessica

AU - Reck, Martin

PY - 2018/12/28

Y1 - 2018/12/28

N2 - INTRODUCTION: Small cell lung cancer (SCLC) is a tumor with a poor prognosis, often diagnosed in an advanced stage. Despite aggressive treatment of early and locally advanced disease, SCLC often relapses. First line chemotherapy provides good response rates in advanced disease, but progression free and overall survival are limited. New drugs such as some targeted therapies and immune therapies are promising in SCLC. Areas covered: In this review, we discuss the preclinical rationale and trial data for targeted therapies and immune therapies in SCLC, with a specific focus on clinical trials. Expert commentary: Lack of identification of clear prognostic and predictive biomarkers has limited the advances in treatment efficacy. This has most likely been the main cause of failure for compounds tested so far. Due to the highly mutational profile and the rapid growth pattern of SCLC, immunotherapy combined with chemotherapy seems the most promising treatment option. Concerning targeted agents, achievements made so far are small, but DLL3-antibodies or combinations of PARPi and immunotherapy could be very promising. These promising strategies also need testing in limited disease.

AB - INTRODUCTION: Small cell lung cancer (SCLC) is a tumor with a poor prognosis, often diagnosed in an advanced stage. Despite aggressive treatment of early and locally advanced disease, SCLC often relapses. First line chemotherapy provides good response rates in advanced disease, but progression free and overall survival are limited. New drugs such as some targeted therapies and immune therapies are promising in SCLC. Areas covered: In this review, we discuss the preclinical rationale and trial data for targeted therapies and immune therapies in SCLC, with a specific focus on clinical trials. Expert commentary: Lack of identification of clear prognostic and predictive biomarkers has limited the advances in treatment efficacy. This has most likely been the main cause of failure for compounds tested so far. Due to the highly mutational profile and the rapid growth pattern of SCLC, immunotherapy combined with chemotherapy seems the most promising treatment option. Concerning targeted agents, achievements made so far are small, but DLL3-antibodies or combinations of PARPi and immunotherapy could be very promising. These promising strategies also need testing in limited disease.

U2 - 10.1080/14737140.2019.1559057

DO - 10.1080/14737140.2019.1559057

M3 - Article

C2 - 30590971

SP - 1

EP - 17

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

ER -